钙调神经磷酸酶抑制剂通过抑制供者T细胞终末耗竭阻碍异基因造血干细胞移植后的免疫耐受诱导
该研究在小鼠异基因造血干细胞移植(HCT)模型中探讨钙调神经磷酸酶抑制剂环孢素(CSP)对供者T细胞耗竭分化和免疫耐受的影响。结果显示,CSP抑制供者T细胞表达TOX,阻断一过性耗竭T细胞向终末耗竭T细胞分化,从而抑制免疫耐受诱导;过继转移一过性耗竭T细胞而非终末耗竭T细胞可诱导慢性移植物抗宿主病(cGVHD)。
要点
- 异基因HCT后供者反应性T细胞快速分化为PD-1+ TIGIT+终末耗竭T细胞。
- 环孢素抑制供者T细胞表达TOX,阻断一过性耗竭T细胞向终末耗竭T细胞分化。
- 过继转移一过性耗竭T细胞而非终末耗竭T细胞可诱导cGVHD。
核心结论
- 环孢素通过抑制供者T细胞终末耗竭而抑制免疫耐受诱导,同时维持移植物抗白血病效应以抑制白血病复发。
研究设计与样本
- 研究在小鼠异基因造血干细胞移植(HCT)模型中进行。
主要发现
- 异基因HCT后,供者反应性T细胞快速分化为PD-1+ TIGIT+终末耗竭T细胞(terminal Tex)。
- 环孢素预防移植物抗宿主病(GVHD)抑制供者T细胞表达TOX,TOX是促进一过性耗竭T细胞(transitory Tex)向终末耗竭T细胞分化的主要调控因子,并抑制免疫耐受诱导。
- 将一过性耗竭T细胞而非终末耗竭T细胞过继转移至二次受体可诱导慢性移植物抗宿主病(cGVHD)。
- 一过性耗竭T细胞维持同种反应性,PD-1阻断恢复一过性耗竭T细胞而非终末耗竭T细胞的移植物抗白血病(GVL)活性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis is standard in allogeneic hematopoietic stem cell transplantation (HCT) but fails to induce long-term tolerance without chronic GVHD (cGVHD) in a considerable number of patients. In this study, we addressed this long-standing question in mouse models of HCT. After HCT, alloreactive donor T cells rapidly differentiated into PD-1+ TIGIT+ terminally exhausted T cells (terminal Tex). GVHD prophylaxis with cyclosporine (CSP) suppressed donor T-cell expression of TOX, a master regulator to promote differentiation of transitory exhausted T cells (transitory Tex), expressing both inhibitory receptors and effector molecules, into terminal Tex, and inhibited tolerance induction. Adoptive transfer of transitory Tex, but not terminal Tex, into secondary recipients developed cGVHD. Transitory Tex maintained alloreactivity and thus PD-1 blockade restored graft-versus-leukemia (GVL) activity of transitory Tex and not terminal Tex. In conclusion, CSP inhibits tolerance induction by suppressing the terminal exhaustion of donor T cells, while maintaining GVL effects to suppress leukemia relapse.
引用
- Senjo H, Harada S, Kubota SI, et al. Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT. Blood. 2023. PMID: 37216687. doi:10.1182/blood.2023019875
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。